4
Changes in Ownership
Mineralys Therapeutics, Inc. Filed Acc 0001916048-26-000012
Chief Commercial Officer sold 7,437 shares at $25.98 ($193,189)
- Chief Commercial Officer acquired 7,437 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Warren Eric Chief Commercial Officer | 2026-08-21 | Option exercise 10b5-1 | +7,437 | $13.24 | $98,466 | 45,837 | D: show line 1 in the form |
| Warren Eric Chief Commercial Officer | 2026-08-21 | Sale 10b5-1 | −7,437 | $25.98 | $193,189 | 38,400 | D: show line 2 in the form |
| Open-market sales · 7,437 sh · avg $25.98 · $193,189 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Warren Eric Chief Commercial Officer | 2026-08-21 | Option exercise · Stock Option 10b5-1 | −7,437 | 238,001 | D: show line 3 in the form |
Loading xslF345X06/wk-form4_1787692603.xml…